59796-99-5

Usage

Chemical structure

A heterocyclic compound with a complex structure belonging to the pyrimidine family.

Nitrogen atoms

Contains two nitrogen atoms in its ring structure.

Appearance

Likely a solid, although the exact appearance is not provided in the material.

Field of application

Used in the field of medicinal chemistry and drug discovery.

Potential use

Can be potentially useful as a pharmaceutical agent.

Research value

Its unique structure and properties make it valuable for research in the development of new drugs and therapeutic treatments.

Additional applications

May have applications in other scientific fields such as organic chemistry and materials science.
Please note that some properties, such as solubility, melting point, and boiling point, are not provided in the material. Further research or experimentation would be required to determine these properties.

Upstream product

• 6642-31-5 6-Amino-1,3-dimethylbarbituric acid 
• 614-47-1 1,3-diphenyl-propen-3-one 
• 769-42-6 1,3-dimethylbarbituric acid 
• 7338-94-5 1,3-diphenyl-2-propynone 
• 93-97-0 benzoic acid anhydride 
• 536-74-3 phenylacetylene 
• 54890-67-4 1,3-dimethyl-5-(3-oxo-1,3-diphenylpropyl)pyrimidine-2,4,6(1H,3H,5H)-trione 
• 78016-80-5 5,6-Dihydro-1,3-dimethyl-5,7-diphenyl-6-(1,3-diphenyl-3-oxoprop-1-yl)-pyrido<2,3-d>pyrimidin-2,4-(1H,3H)-dion 

Relevant academic research and scientific papers

Ferrocenyl, Alkyl, and Aryl-Pyrido[2,3-d]Pyrimidines as Vasorelaxant of Smooth Muscle of Rat Aorta via cAMP Conservation Through Phosphodiesterase Inhibition

New pyrido[2,3-d]pyrimidines 11, 12, 13, and 21 have been synthesized. The vasorelaxant effect on smooth muscle isolated from rat aorta, via PDEs inhibition, of these compounds along with other pyrido[2,3-d]pyrimidines 14, 15, 16, 17, 18, 19, 20 reported earlier by our group, has also been determined. These pyrido[2,3-d]pyrimidines 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 were synthesized by the reaction of ferrocenyl-ethynyl ketones (1, 2, 3, 4) or α-alkynyl ketones (5, 6, 7, 8, 9, 10) with 6-amino-1,3-dimethyluracil using [Ni(CN)4]?4as an active catalytic species, formed in situ in a Ni(CN)2/NaOH/H2O/CO/KCN aqueous system. Evaluation of the vasorelaxant effect of compounds 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 demonstrated that all compounds relax the tissue in a concentration-dependent manner. The structural changes do not alter the effectiveness; however, there are differences related to potency expressed as EC50. Compounds 12 (7-ferrocenyl-1,3-dimethyl-5-(m-tolyl)-pyrido[2,3-d]pyrimidine) and 13 (7-ferrocenyl-1,3-dipropyl-5-(4-metoxyphenyl)-pyrido[2,3-d]pyrimidine) were the most potent compounds, even more than rolipram, reference drug; the EC50was 0.41 ± 0.02 μM and 0.81 ± 0.11 μM for 12 and 13, correspondingly. The EC50of compounds 15 (7-ferrocenyl-1,3-dimethyl-5-phenyl-pyrido[2,3-d]pyrimidine), 14 (7-ferrocenyl-5-(3,5-dimethoxyphenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine), and 19 (5-n-butyl-7-ethyl-1,3-dimethylpyrido[2,3-d]pyrimidine) was similar to EC50of rolipram. Compounds 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 significantly induce concentration-dependent vasorelaxation in endothelium-intact aortic rings. In addition, the relaxation responses to each compound in either endothelium-intact or endothelium denuded aortic rings were comparable, suggesting that removal of the functional endothelium has no significant influence on its intrinsic vasorelaxant activity. In vitro capability of conserving cyclic-AMP or cyclic-GMP (adenosine and guanosine 3′, 5′-cyclic monophosphate) via PDE inhibition for compounds 12, 13, 14, 15 and 19 was evaluated. Compounds 15 and 19 show the highest percent inhibition effect (94.83% and 83.98%, respectively) for the decomposition of c-AMP. Docking studies showed that the compound 15 was selective for the inhibition of PDE-4.

Automated parallel synthesis of chalcone-based screening libraries

Using a variety of condensation and cyclization reactions, nine combinatorial arrays of individual chalcone derivatives, over 74,000 in all, were produced in 50 μM quantities. The ease with which a broad range of diversity can be fabricated around a single molecular motif using automated parallel solution phase synthesis has been demonstrated.

Peculiar reaction behaviour of barbituric acid derivatives towards aromatic amines

5-Benzoylethyl barbituric acid derivatives 2a-c were prepared as useful precursors for the synthesis of pyrimidine fused heterocycles. Their behaviour as 1,5-diketocompounds towards aniline derivatives afforded the pyrimidoquinoline derivatives 6a-e. On t

Michael-additions of 6-aminopyrimidin-4-ones to enones: Semi-empirical MO calculations and experimental investigations

AM1- and PM3 calculations reveal a satisfactory correlation between the charge densities at the C-5 atom (q(C-5), Table 2) of compounds 1, 2, 4a-c and their enamine-like nucleophilicity towards enones 3 and 9. Furthermore, in this series the similarity of

Synthesis of Heterocycles : Part IV - Pyridopyrimidines

5,7-Disubstituted pyridopyrimidine-2,4-diones (Va-c) have been synthesized by a new route involving Michael addition of 1,3-dimethyl-6-iminouracil (I) to α-enones (IIa-c).Reaction of I and benzalacetone (IId) furnishes 9H-pyrimido-quinoline derivatives (VI, VII).